What is Bantam Pharmaceutical?
Bantam Pharma is dedicated to pioneering novel, first-in-class small molecule oral therapeutics designed for challenging hematological and solid tumors. Their primary candidate, BTM-3566, aims to re-establish apoptosis in cancer cells, demonstrating encouraging preclinical outcomes, particularly in Diffuse Large B-cell Lymphoma. The company capitalizes on its deep understanding of mitochondrial dynamics to drive innovation in oncology treatments, positioning itself for accelerated product development within the sector.
How much funding has Bantam Pharmaceutical raised?
Bantam Pharmaceutical has raised a total of $25M across 1 funding round:
Angel/Seed
$25M
Angel/Seed (2021): $25M, investors not publicly disclosed
What's next for Bantam Pharmaceutical?
The substantial enterprise-level funding and recent strategic investment signal a pivotal phase for Bantam Pharmaceutical, likely focused on advancing its lead candidate, BTM-3566, through critical clinical development stages. This capital infusion is expected to fuel rigorous research, expand the scientific team, and navigate the complex regulatory pathways necessary for bringing innovative cancer therapies to market. The company's capital-efficient model suggests a strategic approach to maximizing the impact of this financing, aiming for significant milestones in the oncology landscape.
See full Bantam Pharmaceutical company page
